JP2017160212A5 - - Google Patents

Download PDF

Info

Publication number
JP2017160212A5
JP2017160212A5 JP2017074526A JP2017074526A JP2017160212A5 JP 2017160212 A5 JP2017160212 A5 JP 2017160212A5 JP 2017074526 A JP2017074526 A JP 2017074526A JP 2017074526 A JP2017074526 A JP 2017074526A JP 2017160212 A5 JP2017160212 A5 JP 2017160212A5
Authority
JP
Japan
Prior art keywords
insulin
per day
dapagliflozin
dosage
rosiglitazone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017074526A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017160212A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017160212A publication Critical patent/JP2017160212A/ja
Publication of JP2017160212A5 publication Critical patent/JP2017160212A5/ja
Pending legal-status Critical Current

Links

JP2017074526A 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法 Pending JP2017160212A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18144209P 2009-05-27 2009-05-27
US61/181,442 2009-05-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015241499A Division JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Publications (2)

Publication Number Publication Date
JP2017160212A JP2017160212A (ja) 2017-09-14
JP2017160212A5 true JP2017160212A5 (enExample) 2018-03-01

Family

ID=42334303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2017074526A Pending JP2017160212A (ja) 2009-05-27 2017-04-04 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012513184A Withdrawn JP2012528170A (ja) 2009-05-27 2010-05-26 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法
JP2015241499A Pending JP2016104753A (ja) 2009-05-27 2015-12-10 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法

Country Status (5)

Country Link
US (1) US8685934B2 (enExample)
EP (1) EP2435033A1 (enExample)
JP (3) JP2012528170A (enExample)
CN (2) CN106075451A (enExample)
WO (1) WO2010138535A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
AP2011005794A0 (en) 2009-02-13 2011-08-31 Boehringer Ingelheim Int Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a furtherantidiabetic agent and uses thereof.
PL2483286T3 (pl) 2009-09-30 2017-04-28 Boehringer Ingelheim International Gmbh Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu
BR112012007085B8 (pt) 2009-09-30 2021-05-25 Boehringer Ingelheim Int processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
UY32919A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
LT2498758T (lt) 2009-11-13 2018-11-26 Astrazeneca Ab Dvisluoksnės tabletės formuluotės
RS57926B1 (sr) 2009-11-13 2019-01-31 Astrazeneca Ab Formulacije tablete sa trenutnim oslobađanjem
US20140088027A1 (en) * 2010-03-30 2014-03-27 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) * 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2013095316A1 (en) * 2011-12-19 2013-06-27 Mahmut Bilgic Synergic combination comprising anti-diabetic agent
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9320727B2 (en) * 2012-08-30 2016-04-26 Taisho Pharmaceutical Co., Ltd Combinations of SGLT 2 inhibitors and antihypertensive drugs
WO2014159151A1 (en) 2013-03-14 2014-10-02 Msd International Gmbh Methods for preparing sglt2 inhibitors
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
HUE058731T2 (hu) 2013-04-18 2022-09-28 Boehringer Ingelheim Int Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai
EP2991999B1 (en) 2013-04-29 2019-05-08 Mapi Pharma Limited Dapagliflozin lactose co-crystal
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
CA2981507A1 (en) * 2015-04-07 2016-10-13 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
JP2019504090A (ja) * 2016-02-03 2019-02-14 ドクター レディズ ラボラトリーズ リミテッド ダサチニブの固体状態形態およびそれらの調製プロセス
AU2017267006B2 (en) * 2016-05-20 2019-07-11 Center Laboratories, Inc. Method of treating hyperglycemia
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
BR112020010831A2 (pt) 2017-11-30 2020-11-10 Idorsia Pharmaceuticals Ltd composição farmacêutica, aprocitentan, e, método
US10639292B2 (en) 2018-04-20 2020-05-05 Center Laboratories, Inc. Method of treating hyperglycemia
KR102695130B1 (ko) 2018-05-31 2024-08-16 후아 메디슨 (상하이) 엘티디. 글루코키나제 활성화제 및 ppar 수용체 활성화제를 함유하는 약제학적 병용물, 조성물, 및 병용 제제, 및 이의 제조 방법 및 용도
WO2019241568A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition
BR112022012436A2 (pt) * 2019-12-24 2022-09-06 Hanmi Pharm Ind Co Ltd Formulação compósita e método para preparar a formulação compósita
IL297208A (en) * 2020-04-10 2022-12-01 Chinook Therapeutics Inc Treatment methods for diabetic kidney disease
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ
KR102838283B1 (ko) * 2020-07-10 2025-07-25 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
TW202220672A (zh) 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法
WO2022091029A1 (en) * 2020-10-30 2022-05-05 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CN114671839B (zh) * 2020-12-25 2024-01-09 天地恒一制药股份有限公司 达格列净的固体形式复合物及其制备方法与应用
WO2023144722A1 (en) * 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
EP4493272A1 (en) * 2022-03-14 2025-01-22 University Of Virginia Patent Foundation Combination sodium-glucose cotransporter inhibitor (sglti)- insulin therapy for glycemic control in type 1 diabetes
EP4385502A1 (en) * 2022-12-15 2024-06-19 Sanovel Ilac Sanayi Ve Ticaret A.S. A pharmaceutical formulation comprising metformin, pioglitazone and a sglt-2 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
IL149851A0 (en) 2002-05-26 2002-11-10 Yeda Res & Dev Resistin binding proteins, their preparation and use
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2010045656A2 (en) * 2008-10-17 2010-04-22 Nectid, Inc. Novel sglt2 inhibitor dosage forms

Similar Documents

Publication Publication Date Title
JP2017160212A5 (enExample)
JP2011528713A5 (enExample)
JP2011521940A5 (enExample)
JP2013522194A5 (enExample)
JP2009542702A5 (enExample)
JP2009542699A5 (enExample)
AU2016205138A1 (en) ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
JP2018513188A5 (enExample)
JP2019515908A5 (enExample)
JP2015187125A5 (enExample)
BRPI0519471A2 (pt) formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo
JP2020507589A5 (enExample)
KR20210005843A (ko) Glp1r 작용제의 치료적 용도
JP2013532658A5 (enExample)
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
JP2013541583A5 (enExample)
JP2011503044A5 (enExample)
FI4124339T3 (fi) Lääkkeenantojärjestelmiä ja -menetelmiä virtsarakon syövän hoitoon gemsitabiinilla
JP2018138596A5 (enExample)
JP2018509419A5 (enExample)
JP2010511039A5 (enExample)
JP2020536121A5 (enExample)
JP2010500284A5 (enExample)
MX390101B (es) Tratamiento medico que comprende administracion enteral de edaravona
JPWO2021045159A5 (enExample)